Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Drug Usage
Interventions: gabapentin, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Macular Degeneration
Interventions: ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321); Biological
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 1,217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 176
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more

Conditions: Pterygium
Interventions: Ranibizumab; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Human Milk, Neonate, Breast Milk
Interventions: Targeted Fortification, The Miris Human Milk Analyzer; Dietary Supplement · Device
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: Up to 6 Months
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Traumatic Brain Injury
Interventions: Ketogenic Diet; Other
Lead sponsor: Gillette Children's Specialty Healthcare; Other
Eligibility: 2 Years to 17 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Saint Paul, Minnesota

Conditions: Spinal Cord Injury
Interventions: Regular Insulin, 0.9 % Normal Saline; Drug · Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years to 84 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Melanoma
Interventions: Nivolumab, HF10; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Crohns Disease
Interventions: N-Acetylglucosamine (GlcNAc); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sleep Restriction
Interventions: Ketoconazole Pill, Ganirelix, Dexamethasone, Dexamethasone Injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone, Hydrocortisone Injection, Gonadorelin, Corticorelin, Placebo oral capsule, Saline Solution, Saline Solution for Injection; Drug
Lead sponsor: Peter y. Liu; Other
Eligibility: 22 Years to 45 Years · Male only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Torrance, California

Conditions: Type 1 Diabetes Mellitus
Interventions: 180 mg/kg Alpha1-PI, 90 mg/kg Alpha1-PI, Placebo; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 6 Years to 35 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 36
States / cities: Tucson, Arizona • Los Angeles, California • Orange, California + 28 more

Conditions: End Stage Renal Disease
Interventions: basiliximab; Drug
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Crohn's Disease
Interventions: Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Guselkumab Dose 4, Guselkumab Dose 5, Guselkumab, Ustekinumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 109
States / cities: Dothan, Alabama • Mobile, Alabama • Tucson, Arizona + 83 more

Conditions: Dry Eye Disease
Interventions: CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops; Drug
Lead sponsor: Novaliq GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 9
States / cities: Newport Beach, California • Torrance, California • Indianapolis, Indiana + 6 more

Conditions: Type 1 Diabetes
Interventions: DFMO, Placebo; Drug
Lead sponsor: Emily K. Sims; Other
Eligibility: 4 Years to 40 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Aurora, Colorado • Chicago, Illinois • Indianapolis, Indiana + 4 more

Conditions: Interstitial Cystitis
Interventions: Adalimumab, inactive drug; Drug · Other
Lead sponsor: ICStudy, LLC; Other
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Escondido, California

Conditions: Post Acute Coronary Syndrome, Myocardial Ischemia
Interventions: Placebo, Aliskiren 300 mg, Valsartan 320 mg, Aliskiren/valsartan 300/320 mg; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Investigative Site, New Jersey

Conditions: Stomach Cancer, Esophageal Cancer
Interventions: Ramucirumab, Placebo, Oxaliplatin, Leucovorin, 5-Fluorouracil; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 58
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Alhambra, California + 55 more

Conditions: Oligoprogressive
Interventions: IMSA101, Immune checkpoint inhibitor, PULSAR; Drug · Radiation
Lead sponsor: ImmuneSensor Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 14
States / cities: Irvine, California • Los Angeles, California • Chicago, Illinois + 8 more

Conditions: Alcoholic Cirrhosis
Interventions: Placebo, SAMe 400 mg tablet; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • Indianapolis, Indiana

Conditions: Sepsis
Interventions: Suspected Sepsis Group - Diagnostic Measurements, Control Group - Diagnostic Measurements; Diagnostic Test
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Psoriatic Arthritis
Interventions: Etanercept, Methotrexate, Placebo to Etanercept, Placebo to Methotrexate; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 851 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 55
States / cities: Tuscaloosa, Alabama • Glendale, Arizona • Mesa, Arizona + 50 more

Conditions: Diabetes Mellitus, Diabetic Macular Edema
Interventions: ASP8232, ranibizumab, Placebo, Sham intravitreal (IVT) injection; Drug · Other
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 21
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 18 more

Conditions: Sickle Cell Anemia, Thalassemia
Interventions: L-glutamine, Placebo; Drug
Lead sponsor: Emmaus Medical, Inc.; Industry
Eligibility: 5 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 5
States / cities: Bellflower, California • Torrance, California • Atlanta, Georgia + 2 more

Conditions: Peripheral Neuropathy
Interventions: MIRE, Sham Device; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Scottsdale, Arizona

Search by objective public record fields.

Gabapentin as Adjunctive Treatment for Postoperative Pain Control

Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)

Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia

Targeted Breast Milk Fortification for Very Low Birth Weight Infants in the NICU

Ketogenic Diet Following Moderate to Severe Pediatric Traumatic Brain Injury

Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury

Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma

Oral N-acetylglucosamine in Crohn's Disease

Hormonal Mechanisms of Sleep Restriction - Axis Study

Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus

Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

TArgeting Type 1 Diabetes Using POLyamines (TADPOL)

Efficacy Study of Adalimumab to Treat Interstitial Cystitis

Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome

A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

SAMe Trial for Patients With Alcoholic Cirrhosis

Mitochondrial Dysfunction Contributes to Sepsis Induced Cardiac Dysfunction

Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis

A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)

L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia

Near Infrared Light for the Treatment of Painful Peripheral Neuropathy